A new study from Korea looked at exactly that weirdness in the Korean national lung cancer screening program, which uses low-dose CT scans in high-risk people. The researchers analyzed 235,753 participants who had a baseline scan between 2019 and 2021 and stayed lung cancer-free for the next 2 years. Then they asked a deceptively simple question: who actually came back for the next scheduled screening? (Kim et al., 2026)
Overall, 54.4% returned. That number alone is enough to make any screening program manager stare into the middle distance.
But the real plot twist was not just whether someone had a false-positive result. It was what happened after that false positive. People who had a false alarm and then went through invasive procedures were less likely to come back. Same for people sent into CT surveillance. Meanwhile, people with a false positive who had no further evaluation came back at about the same rate as people whose first scan was truly negative (Kim et al., 2026).
That is a big deal. It suggests the scary part is not merely hearing, "We saw something." It is getting pulled into the medical mini-series that follows. Extra scans. Extra worry. Maybe a biopsy. Suddenly your preventive health appointment has turned into a suspense thriller nobody asked for.
When the smoke alarm changes your behavior
Lung cancer screening works, but only if people keep showing up. The whole enterprise is built on repetition. Low-dose CT has been shown to reduce lung cancer mortality in high-risk groups, which is why guidelines support it (Adams et al., 2023). But a screening program is not magic. It is more like airport security: useful, imperfect, and heavily dependent on everyone participating in the same ritual over and over again.
False positives are one of the classic trade-offs. You want the scan sensitive enough to catch cancer early, but that means some harmless findings will still set off alarms. In lung screening, those alarms are especially messy because the lungs are full of random visual clutter from smoking, inflammation, infection, and general biological chaos. The chest is not a minimalist apartment. It is more like a garage with 14 unlabeled boxes.
And yes, this part is where my immune-system-loving brain usually wants to scream about surveillance, infiltration, and tiny cellular bodyguards in tactical gear. This paper is less "T cells rappel through a skylight" and more "public health discovers that paperwork and anxiety can kneecap a lifesaving program." Still dramatic, just with fewer capes.
The people at highest risk may be the ones slipping away
Here is the part that really sticks. In the Korean study, the groups with false positives requiring invasive procedures or CT surveillance were not only less likely to return. They also had higher later risks of lung cancer, and in some groups, higher all-cause mortality (Kim et al., 2026).
That means the folks who may need the closest watch can be the very ones who drift out of the system. If this were a spy movie, the suspect would slip out the back while security argued about the clipboard.
This pattern also fits the broader literature. A 2020 systematic review and meta-analysis in JAMA Network Open found pooled adherence to repeat lung cancer screening in the US was only about 55%, with lower adherence among current smokers and some socially disadvantaged groups (Lopez-Olivo et al., 2020). Another 2021 systematic review and meta-analysis in the Journal of Thoracic Oncology found adherence varies by Lung-RADS category and remains uneven in real-world practice (Lin et al., 2022). A 2025 Korean analysis showed national program uptake has improved substantially over time, which is encouraging, but better participation at the front door does not automatically solve what happens after a nerve-rattling result (Choi et al., 2025).
What this changes in the real world
The practical takeaway is not "false positives are bad, cancel the scanners." That would be like quitting home security because one smoke detector once yelled at your toast.
The real lesson is that screening programs need better recovery plans after a false alarm. Clear communication. Fast explanations. Fewer confusing handoffs. Thoughtful reminders. Maybe even dedicated navigation for people who went through biopsies or prolonged follow-up. The target is not just detecting nodules. It is preserving trust.
Because if reproducible studies keep showing this pattern, the future win is obvious: support the people most rattled by baseline findings so they are not lost before the next round. Early detection only helps if the second act actually happens.
References
Kim H, Jo E, Kim J, Yoon S, Fintelmann FJ, Silvestri GA, Goo JM. Association of baseline screening results and management with subsequent adherence in the Korean national lung cancer screening program. Journal of Internal Medicine. 2026. doi:10.1111/joim.70103
Adams SJ, Stone E, Baldwin DR, Vliegenthart R, Lee P, Fintelmann FJ, et al. Lung cancer screening. The Lancet. 2023;401(10374):390-408. doi:10.1016/S0140-6736(22)01694-4
Lopez-Olivo MA, Maki KG, Choi NJ, Hoffman RM, Shih YCT, Lowenstein LM, et al. Patient adherence to screening for lung cancer in the US: A systematic review and meta-analysis. JAMA Network Open. 2020;3(11):e2025102. doi:10.1001/jamanetworkopen.2020.25102 PMCID:PMC7670313
Lin Y, Fu M, Ding R, Inoue K, Jeon CY, Hsu W, Prosper AE. Patient adherence to Lung CT Screening Reporting and Data System-recommended screening intervals in the United States: A systematic review and meta-analysis. Journal of Thoracic Oncology. 2022;17(1):38-55. doi:10.1016/j.jtho.2021.09.013 PMCID:PMC8692358
Choi CK, Lee NY, Suh M, Choi KS, Kim Y. Changes in uptake, participant disparities, and screening outcomes of the Korean National Lung Cancer Screening Program: A five-year experience. Cancer Research and Treatment. 2025. doi:10.4143/crt.2025.067
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.